This article was originally published in The Gray Sheet
Executive SummaryAcquisition of Thompson Dental for $22 mil. is expected to contribute revenues of $50 mil. on an annualized basis and add a significant share to Patterson's Mid-Atlantic and Southeastern markets, the firm announces April 2. The cash/stock/debt deal will be accretive to earnings in fiscal 2003 and is expected to have a neutral impact on Patterson's consolidated profitability over the balance of fiscal 2002, ending April 27...
You may also be interested in...
Oncology Center of Excellence is reviewing a research report on fluorouracil, and will next look to update cisplatin's label, but eventually must convince the reference product sponsor to submit the changes.
US FDA’s ‘Project Renewal’ requires lots of work and flexibility, Oncology Center of Excellence acknowledges. Side-benefit may be getting outside physicians to appreciate the value of drug labeling.
The pharmaceutical industry would lose bid to eliminate PUPSIT but win relaxed WFI in proposed EU GMP Annex I revision.